<DOC>
	<DOC>NCT00417716</DOC>
	<brief_summary>Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema</brief_summary>
	<brief_title>Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema</brief_title>
	<detailed_description>A non-randomized prospective clinical interventional study which includes 45 non previously treated patients with DME. The patients received a single intravitreal injection of 2.5 mg bevacizumab. Follow-up included clinical examination (best corrected visual acuity (BCVA, intraocular pressure (IOP), cataract grading, DME characteristics and systemic check-up) pre-injection, at first visit, at weeks 1 and 2 and months 1 and 3. OCT and fluorescein angiography was evaluated at months 1 and 3.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Type 2 diabetes Macular edema involving the center of the macula demonstrated on OCT Clear ocular media Untreated patients Older than 45 years BCVA of the fellow eye at least 20/100 Renal diabetic disease, uncontrolled hypertension or stroke history Other ocular disease Ocular surgery excepting uncomplicated phacoemulsification History of photocoagulation (panretinal or focal) History of another intravitreal treatment (like triamcinolone)</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Diffuse Diabetic Macular Edema</keyword>
	<keyword>Intravitreal Bevacizumab</keyword>
	<keyword>Anti-VEGF drugs</keyword>
</DOC>